Clinical trial
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia
NCT05640102 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia
- Lead sponsor
- BeiGene
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- March 3, 2023
- Completion date
- December 31, 2027
- Enrollment
- 111 (estimated)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.